Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir

Abstract

The objective of this retrospective study was to identify the clinical safety profile associated with uric acid elevation in coronavirus disease (COVID-19) patients treated with favipiravir. Uric acid elevation was defined as an unexplained increase of ≥1.5 times in the patient's uric acid level from baseline. Twenty-nine COVID-19 patients were included in the study. Uric acid elevation developed during favipiravir therapy in 12 (41.4%) patients and the median onset time was 4.5 days after starting favipiravir. In multiple logistic regression analysis, the favipiravir dosage (adjusted OR = 1.69 [1.02–2.81], P =0.044) and younger patient age (adjusted OR = 0.91 [0.83–0.99], P =0.040) were significant clinical risk factors for uric acid elevation. No significant between-group difference was noted in the uric acid elevation and non-elevation groups in the clinical recovery after favipiravir therapy. The uric acid levels of patients administered with favipiravir should be monitored closely.

Identification of potential Indonesian marine invertebrate bioactive compounds as TMPRSS2 and SARS-CoV-2 Omicron spike protein inhibitors through computational screening

“…According to preclinical trials, case reports, and clinical trials, current COVID-19 antivirals have limitations, such as the possibility of side effects and significant drug interactions ( Brunetti et al, 2021 , Hanai et al, 2022 , Koseki et al, 2022 , Touafchia et al, 2021 , U.S. Food and Drug Administration, 2022 ). Therefore, research on new anti-SARS-CoV-2 drugs as a better therapeutic option is essential.…”

Review: Natural Bioactive Compounds Potential on Inhibition of Transmembrane Serine Protease 2 With Structure-Based Virtual Screening Method

“…Based on the 4th edition of the Guidelines for the Management of COVID-19, the antivirals of choice for patients with confirmed COVID-19 in Indonesia are favipiravir, molnupiravir, paxlovid (a combination of nirmatrelvir and ritonavir), and remdesivir (Burhan et al, 2022). However, there are still limitations to the currently available antivirals for COVID-19, such as the occurrence of side effects and the potential for significant drug interactions based on preclinical trials, case reports, and clinical trials (Brunetti et al, 2021;Hanai et al, 2022;Koseki et al, 2022;Touafchia et al, 2021;U.S. Food andDrug Administration, 2022a, 2022b).…”